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 Implication for health policy/practice/research/medical education:
This paper strongly suggests the importance of large scale vaccination of live attenuated hepatitis A vaccine in preventing people 
from the hepatitis A. It is helpful to governors, health workers, clinical doctors, medical students and researchers in this ﬁeld. 
Background: Hepatitis A was ranked ﬁrst among all of the diﬀerent types of viral hepatitis 
in China, which occurred an average of 500,000 cases annually during the 1980’s. A live 
attenuated hepatitis A vaccine was applied in preventing of the disease in 1992, large 
scale used in vaccination program in 1995, and incorporated in the Expanded Program 
of Immunization in 2008 in China.
Objective: The objective of this study was to determine whether, and to what extent, the 
decline in the incidence of hepatitis A in China was the result of hepatitis A (HA) vaccina-
tion.
Materials and Methods: Oﬃcial documents and longitudinal serological follow-up stud-
ies were reviewed to compare the incidence of HA before and after the introduction of 
the vaccine.
Results: National trends in the incidence of HA in China saw rates decrease by 92.7% in 
2009, compared to the levels seen in 1992. A mass vaccination program was carried out 
in 3-18 year old children (Wuhan City, China), and its protective eﬃcacy was 85.4%. In a 
mass vaccination program of an entire population (Shenshi County, China), the annual 
HA incidence decreased from 359.7/100,000 to 17.7/100,000 (almost 20.3 times). There 
was a signiﬁcant relationship found between vaccine coverage and the incidence of HA, 
the correlation of the negative regression was signiﬁcant at the 1% (Kendall rank correla-
tion, signiﬁcant level P < 0.05).
Conclusions: In summary, this study highlights the important role of implementing a 
vaccination program in decreasing the incidence of HA, and the large protective eﬃcacy 
of such a strategy, as demonstrated in China.
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1. Background
Hepatitis A (HA) is an acute infectious disease caused 
by the hepatitis A virus (HAV). HA usually occurs in the 
form of a local epidemic, and it is mainly transmitted via 
the fecal-oral route. It is estimated that the world-wide 
incidence of the disease exceeds 1.4 million cases each 
year, with the health cost being between 1.5 to 3.0 bil-
lion dollars annually (1). HA is also ranked ﬁrst occurred 
cases among all of the diﬀerent types of viral hepatitis in 
China, especially in the southeast coastal areas. An aver-
age of 500,000 HA cases were reported annually to the 
Ministry of Health (MOH) in China during the 1980s, this 
ﬁgure represents approximately 5.5 million infections 
per year when anicteric disease and asymptomatic infec-
tions are taken into account as well. During a shellﬁsh-
associated outbreak of HA in 1988, in Shanghai, China, 
approximately 320,000 cases were reported (2). In the 
year 1990, the incidence of HA was 52.58/100,000 in Chi-
na, and 114.90/100,000 in the Zhejiang Province (located 
in the southeast region of China). In 1992, a live attenu-
ated hepatitis A vaccine (H2 strain) became available in 
China for use among children aged 1 year or older. The 
vaccine was developed and licensed by State Food and 
Drug Administration (SFDA), China (3, 4), and meets the 
requirements of both SFDA China and the World Health 
Organization (WHO) for the manufacture of biological 
substances (5, 6). In 1995, the Advisory Committee on Im-
munization Practice from the Center for Disease Control 
(CDC) in China recommended a target of HA vaccination 
for selected high-risk populations such as; children aged 
1 to 15 years, medical practitioners employees in food 
factories, and residents in endemic regions. In 2008, 
the Chinese MOH incorporated the vaccine into the Ex-
panded Program of Immunization (EPI) in China, which 
means that in this program all infants aged 1 year are im-
munized free of charge. Inﬂuenced by this policy, vaccine 
coverage was well accepted in the target population. The 
vaccine is now widely included in immunization pro-
grams to prevent HA epidemics in China, as well as in a 
number of other countries (7, 8).
2. Objectives
The objective of this study was to determine whether 
the decreasing incidence of HA seen in China was the re-
sult of HA vaccination, and if so, to what extent this could 
be attributed to the program. 
3. Materials and Methods
The incidence of HA per 100,000 people was deter-
mined by using the data from HA cases reported through 
the National Infectious Disease Surveillance System 
(NIDSS) under the leadership of the national Chinese 
Center for Disease Control and Prevention (CDC). A re-
portable case was deﬁned as an acute illness with the dis-
crete onset of symptoms and jaundice, and/or elevated 
serum aminotransferase levels in a person who tested 
positive for the IgM antibody to the HA virus. HA infec-
tions are reportable by law from clinics in rural areas and 
hospitals to the local county CDC in all jurisdictions that 
report to the NIDSS. The 4th Chinese National Census in 
1990 estimated the population to be approximately 1.16 
billion, and in the 5th National Census in 2000 it was ap-
proximately 1.3 billion. More detailed national level esti-
mates by; age, sex, race, and ethnicity in 1990 and 2000, 
were obtained from the National Census Bureau, and 
regional data was obtained from the Regional Census 
Bureau. Oﬃcial documents and policy decisions in the 
ﬁeld of HA vaccination were reviewed and its use in the 
EPI were also employed. Some data from the longitudi-
nal serological follow-up studies (9) was used to compare 
the incidence of HA before and after the introduction of 
the HA vaccine. Based on these data, the relationship be-
tween the annual HA incidence and vaccine coverage was 
analyzed. Most of the data was collected from Wuhan (a 
large city in the central region of China), and from Shensi 
County and Jiaojiang City (located in the east coast areas 
of the Zhejiang Province, China).
4. Results
4.1. National Trends in Hepatitis A Incidence in China
Before the 1990s, there were several peaks of HA out-
breaks occurring over a period of 8-10 years, the high-
est peak was in 1989 (768,000 cases, 62.63/100,000), the 
main contributors to the HA outbreak were infected 
cases from Shanghai and the eastern provinces of China. 
Between 1990 to1992 the annual incidence of HA in China 
Figure 1. Relationship Between Vaccine Output and HA Incidence 
(1/100,000) in China from 1990-2006
1983-1989 before vaccination; 1990-1991 clinical III trial; 1992-2002 mass 
vaccination program. Kensall RankTest τ2 = -0.931, P2 < 0.01.
Figure 2. Correlation Between Vaccine Coverage and HA Incidence in 1–5 
Year Old Children Group102
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was 50/100,000. The live H2 strain vaccine was adminis-
trated in 1992 and from that time the incidence of HA 
gradually decreased. In 2009, the rate of 3.57 per 100,000 
(43,841 reported cases) was 92.7% lower than that in 1992 
(49.08 per 100,000, among 602,591 reported cases) (Table 
1).
4.2. Correlation of the National Hepatitis A Incidence 
With Hepatitis A Vaccine Output
The national incidence rate of HA decreased dramati-
cally from 1992 to 2006. During the same period, the an-
nual cumulative output of a live attenuated (H2 strain) 
HA vaccine from a major manufacturer, (Pukang Com-
pany, located in Hangzhou, China) increased from 2.9 
million doses in 1992 to 138.2 million doses in 2006 (165.3 
million doses in 2009) (Figure 1).
4.3. The Protective Eﬃcacy of Live Attenuated Hepatitis 
A Vaccine in the Mass Vaccination Program
1. Protective eﬃcacy in Wuhan City by mass vaccination 
(Table 2)
2. The mean of the annual HA incidence in the total pop-
ulation of the Shenshi County was 359.7/100,000 before 
the vaccine was applied (from 1983 to 1989), and a nota-
ble decrease to 17.7/100,000 (almost 20.3 times less) took 
place after vaccination was implemented (from 1990 
to 1999). By comparing the number of HA cases before 
and after vaccination, it is clear that the number of HA 
cases decreased from several hundred to zero, especially 
among children from 1 to 15 years old (Table 3).
3. A signiﬁcant correlation was found between vaccine 
coverage and HA incidence. Before 1989, there were no 
HA vaccinations in the Shengsi County and Jiaojiang 
City. From 1990 to 1991, the H2 strain vaccine clinical 
phase Ⅲ trial was initiated in these two regions, and a 
mass vaccination project focusing mainly on 1-15 year old 
children has been ongoing since 1992. Vaccine coverage 
has improved annually, and the incidence of HA in these 
locations has decreased dramatically (Figure 2). During 
the years 1996 to 1998 vaccine coverage increased rapidly 
from 57.22% to 74.28%, and only 2 cases were found, nei-
ther of which were among people who had been vacci-
nated. In Jiaojiang City vaccine coverage reached 88.73% 
in 1994 during the early stages of the project, and re-
mained at a steady level between 84.75% and 91.12% in the 
following years. So far there has not been any HA cases in 
this susceptible group at any point in the 9 year period 
between 1994 and 2002. The correlation of negative re-
gression between vaccine coverage and the HA incidence 
rate was signiﬁcant at the 1% level using the Kendall rank 
correlation test (τ1 = -0.825, P1 < 0.01; τ2 = -0.931, P2 < 0.01). 
Through the mass vaccination project, the incidence rate 
of HA in these two regions has dropped dramatically by 
more than 95% (10).
5. Discussion
This current report describes a dramatic decline in the 
incidence of HA in China. The reported rate of HA was 
47.60 per 100,000 in the population in 1990, in contrast, 
this rate decreased to only 3.57 per 100,000 people in 
Annual HA Cases Annual Incidence of 
HA(1/100,000)b
Year Annual HA Cases Annual Incidence of 
HA(1/100,000)b
1990 a 584.353 47.60 2000 a 134.094 10.92
1991 637.717 51.95 2001 121.532 9.90
1992 602.591 49.08 2002 111.068 9.05
1993 457.895 37.30 2003 99.383 8.10
1994 353.388 28.79 2004 93.587 7.62
1995 254.242 20.71 2005 73.349 5.97
1996 238.331 19.41 2006 68.667 5.59
1997 215.844 17.58 2007 77.135 6.28
1998 183.373 14.94 2008 56.052 4.57
1999 203.177 16.55 2009 43.841 3.57
 Table 1. Hepatitis A Incidence in China from 1990 to 2009
a Total population in China in 1990: 1.160 billion, No.4 National Population Census; in 2000: 1.295 billion, No.5 National Population Census.
b Annual incidence of HA is calculated from the veriﬁed data from the 1990 and 2000 censuses .
HA Incidence in December 1993(1/100,000) HA Incidence in December 1994(1/100,000) Protective Eﬃcacy, %
3-6, y 290.81 49.94 82.82
7-12, y 272.94 19.55 92.84
13-18, y 123.91 31.02 74.97
Total (3-18, y) 229.22 33.50 85.40
Table 2. HA Vaccine Protective Eﬃcacy in Wuhan City by Mass Vaccination in 1994103
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2009. This decline was more signiﬁcant in the eastern 
regions where the vaccination program has had a major 
impact; on the other hand this level of rate decrease ap-
plied less in the western regions. In 2009, the incidence 
of HA was the lowest level recorded according to all re-
cords in 20 years of surveilance, and the provisional 2009 
rate of 3.57 reported cases per 100,000 represented yet a 
further decrease. This decline coincided with the imple-
mentation of the EPI programme of HA vaccination for 
children. It should be noted that the greater decrease in 
incidence rates of HA in children (especially between 1-15 
years) may have resulted in a shift in the age proﬁle of 
reported cases. This fundamental shift in the epidemio-
logic patterns of HA has accompanied the decline in de-
creased rates in all age groups, as is shown in the data (10, 
11) from both Shensi County and Jiaojiang City. 
Simultaneously, along with the vaccination program, 
peoples’ sanitation conditions have also improved and 
lifestyle changes may also have contributed to the de-
crease in the incidence rates, however the vaccination 
program is considered to have had the major impact (2). 
Determining the role of vaccination which has resulted 
in the observed changes in HA epidemiology is compli-
cated by the historical incidence patterns of HA, and also 
by improvements in Chinese sanitation conditions and 
peoples’ lifestyles. Unfortunately, there is no data that 
allows the various components of this decline to be dif-
ferentiated, therefore, the proportion of the decrease 
resulting from improvements in socio-economic status 
and the proportion of the decline that is attributable to 
the use of the vaccine cannot be accurately determined 
(2). Nevertheless, it can be concluded that the HA vaccine 
has played a remarkable role in the decreasing incidence 
of HA. 
HA was the main infectious disease in Wuhan City in 
the central area of China before 1993, and the annual av-
erage incidence of HA was 215.14 per 100,000 from 1984 
to 1993. A mass vaccination program was carried out by 
the CDC in Wuhan City in Dec. 1993 with the target popu-
lation being children aged 3 to 18 years. The average pro-
tective eﬃcacy was 85.4% (12). Shensi County, an island 
in the east of the Zhejiang Province in China, had a high 
HA incidence before 1990. Taking its special geographi-
cal location into consideration, a mass vaccination was 
carried out in 1-15 year old children in order to reach the 
goal of eliminating HA cases from occurring in this area. 
The ﬁrst vaccine program that began in March 1990, was 
named the live HA vaccine clinical III trial. Almost all of 
the children aged 1-15 years were inoculated with a live 
vaccine giving coverage of 90%, other people such as 
those working in the food industry and medical clinics 
were also inoculated. In the following years, the vaccine 
eﬀectively prevented the occurrence of HA under the sur-
veillance of the local CDC doctors. Only one HA case was 
found in the whole population, and that person had not 
been vaccinated (one HA case occurred in 1997, 1998, and 
Whole Population Children 1-15 Years
HA Cases HA Incidence (1/100,000) Mean Pop/Annually HA cases HA Incidence (1/100,000)
Before Vaccine Inoculation
1983 81780 239 292.25 22004 191 868.02
1984 81622 245 300.16 21078 196 929.84
1985 82310 147 178.59 19907 116 582.71
1986 82750 234 282.78 19458 185 950.77
1987 83320 244 292.85 18745 195 1040.78
1988 83579 789 944.02 16902 563 3330.96
1989 84214 187 222.06 18109 150 828.32
After Vaccine Inoculation
1990 a 84652 42 49.61 18139 14 77.18
1991 a 85209 44 51.64 18279 15 82.29
1992 85603 20 23.36 18446 11 59.63
1993 85850 17 19.80 18473 7 37.89
1994 85890 9 10.48 18450 3 16.26
1995 86207 10 11.60 18837 7 37.16
1996 86314 7 8.11 19030 1 5.25
1997 86041 1 1.16 17285 0 0.00
1998 85550 1 1.17 16631 1 6.01
1999 85264 1 1.17 15131 0 0.00
Table 3. The Diﬀerence of Hepatitis A Incidence in Shengsi County Before and After Live HA Vaccination
a Clinical III trial carried out in 1990 and 1991104
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1999 separately). Since then, there have been no further 
HA epidemics in the entire county, thanks to the mass 
vaccination program (9). Before 1989, HA cases were re-
ported annually, ranging from 75 to 140 (average 102 HA 
case/year) in Shengsi County, and from 21 to 87 (average 
38 HA case/year) in Jiaojiang City. Because there was only 
an insigniﬁcant change of the 1-15 year group population 
(less than 1,600 changed in 85,264 in whole 1-15 year aged 
population Shensi County and 84,614 in aged population 
Jiaojing City), the measurement of HA case/year was used 
as an indicator in (Figure 2). Comprehensive information 
on HA coverage could provide a useful context in which 
to interpret the key ﬁndings presented in this report. 
Unfortunately, only very limited data are available and 
vaccination coverage among adults is not assessed. How-
ever, the available information indicates that HA vaccine 
coverage in the high risk group (1-15 year old children) in 
this research region is high. From the trial, it has been 
revealed that there was a signiﬁcant negative correlation 
between vaccine coverage and HA incidence rates (13). 
This available information concerning vaccine use, indi-
cates that the observed declines in rates among children 
appear to have been achieved with a modest level of vac-
cination coverage, supporting the hypothesis of a strong 
herd immunity eﬀect. 
When vaccine coverage is relatively high (> 80%), the 
group would be more likely to develop immune herd 
protection as a result. Additional evidence of such an 
eﬀect was seen in Shengsi County where the vaccine of 
children (approximately 42% in 1992 increased to 89% in 
1999) resulted in a substantial reduction in disease rates 
in adults. Similar ﬁndings have been reported from oth-
er countries in which routine HA vaccination of infants 
or children has been implemented (14, 15). A recent arti-
cle that explains the results of modeling the relationship 
between HA incidence and vaccine coverage also found a 
strong herd immunity eﬀect, accounting for more than 
one third of the estimated number of cases prevented 
by vaccination (16). The HA incidence rates from 1990 to 
1992 were used as baseline rates and therefore represent-
ed the pre-vaccination era, because HA incidence had var-
ied almost equally except for the peak in 1998. The base-
line rates were compared with those of the most recent 
years rather than with the average from multiple years, 
because implementation of the vaccination had oc-
curred in stages in diﬀerent provinces (17), and was still 
expanding, thus there was no well-deﬁned post vaccina-
tion period. Our analyses used passive surveillance data 
reported through the NIDSS, which collects information 
on symptomatic, serological conﬁrmed HA cases, and 
this has a number of previously described limitations. 
These reports represent only a portion of all infections, 
due to the fact that asymptomatic infections and some 
symptomatic cases are not reported. The incidence HA 
has historically exhibited a pattern of periodic ﬂuctua-
tion, thus further monitoring in the future is required in 
order to determine the extent to which the declines that 
have occurred will be sustained, and can be attributed to 
vaccination (11, 18). In addition, more data on vaccine cov-
erage levels are needed to better describe the relation-
ship between HA vaccine usage and disease rates. 
In summary, implementation of this vaccination strat-
egy revealed a signiﬁcant decrease in the incidence of 
HA in children and a large herd immunity eﬀect. All the 
above mentioned results demonstrate that the H2 strain 
vaccine can and will play an important role in prevent-
ing and controlling future HA epidemics in China.
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